News >

Published Ramucirumab/Erlotinib Data Showcase PFS Benefit in Frontline EGFR+ NSCLC

Gina Columbus
Published: Monday, Oct 07, 2019

Kazuhiko Nakagawa, MD

Kazuhiko Nakagawa, MD

The combination of ramucirumab (Cyramza) and erlotinib (Tarceva) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus erlotinib alone in treatment-naïve patients with EGFR-mutant non–small cell lung cancer (NSCLC), according to results of the phase III RELAY trial that have now been published in The Lancet Oncology.1,2
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication